1-12 of 12
Luigi Formisano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, Mireia Margeli Vila, Antonio Antón, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesús Herranz, Daniel Fernández-García, Rosalía Caballero, José Antonio López-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martín
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1557–1568.
https://doi.org/10.1158/1078-0432.CCR-22-2206
Published: 14 April 2023
View article titled, <em>CCNE1</em> and <em>PLK1</em> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Open the PDF for <em>CCNE1</em> and <em>PLK1</em> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer

Alberto Servetto, Rahul Kollipara, Luigi Formisano, Chang-Ching Lin, Kyung-Min Lee, Dhivya R. Sudhan, Paula I. Gonzalez-Ericsson, Sumanta Chatterjee, Angel Guerrero-Zotano, Saurabh Mendiratta, Hiroaki Akamatsu, Nicholas James, Roberto Bianco, Ariella B. Hanker, Ralf Kittler, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4379–4396.
https://doi.org/10.1158/1078-0432.CCR-20-3905
Published: 01 August 2021
View article titled, Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER<sup>+</sup> Breast Cancer
Open the PDF for Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER<sup>+</sup> Breast Cancer in another window
Journal Articles

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Joshua Z. Drago, Luigi Formisano, Dejan Juric, Andrzej Niemierko, Alberto Servetto, Seth A. Wander, Laura M. Spring, Neelima Vidula, Jerry Younger, Jeffrey Peppercorn, Megan Yuen, Giuliana Malvarosa, Dennis Sgroi, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, A. John Iafrate, Carlos L. Arteaga, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6443–6451.
https://doi.org/10.1158/1078-0432.CCR-19-0138
Published: 01 November 2019
View article titled, <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer
Open the PDF for <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bhola, Angel L. Guerrero-Zotano, Valerie M. Jansen, Mónica M. Estrada, Katherine E. Hutchinson, Jennifer M. Giltnane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda Sanders, Teresa C. Dugger, Roberto Bianco, Thomas Stricker, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1433.
https://doi.org/10.1158/1078-0432.CCR-18-4268
Published: 15 February 2019
View article titled, Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer
Open the PDF for Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer in another window
Journal Articles

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1431.
https://doi.org/10.1158/1078-0432.CCR-18-4270
Published: 15 February 2019
View article titled, Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Journal Articles

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

Dhivya R. Sudhan, Luis J. Schwarz, Angel Guerrero-Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González Ericsson, Melinda Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 771–783.
https://doi.org/10.1158/1078-0432.CCR-18-1131
Published: 15 January 2019
View article titled, Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial
Open the PDF for Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial in another window
Includes: Supplementary data
Journal Articles

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. Gonzalez-Ericsson, Dhivya R. Sudhan, Rebecca J. Nagy, Aju Mathew, Eric H. Bernicker, Massimo Cristofanilli, Jie He, Richard E. Cutler, Jr, Alshad S. Lalani, Vincent A. Miller, Richard B. Lanman, Nick V. Grishin, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 277–289.
https://doi.org/10.1158/1078-0432.CCR-18-1544
Published: 03 January 2019
View article titled, Combined Blockade of Activating <em>ERBB2</em> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Open the PDF for Combined Blockade of Activating <em>ERBB2</em> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2517–2529.
https://doi.org/10.1158/1078-0432.CCR-17-2904
Published: 31 May 2018
View article titled, ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Open the PDF for ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bhola, Angel L. Guerrero-Zotano, Valerie M. Jansen, Mónica M. Estrada, Katherine E. Hutchinson, Jennifer M. Giltnane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda Sanders, Teresa C. Dugger, Roberto Bianco, Thomas Stricker, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6138–6150.
https://doi.org/10.1158/1078-0432.CCR-17-1232
Published: 12 October 2017
View article titled, Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer
Open the PDF for Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER<sup>+</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer

Ingrid A. Mayer, Vandana G. Abramson, Luigi Formisano, Justin M. Balko, Mónica V. Estrada, Melinda E. Sanders, Dejan Juric, David Solit, Michael F. Berger, Helen H. Won, Yisheng Li, Lewis C. Cantley, Eric Winer, Carlos L. Arteaga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (1): 26–34.
https://doi.org/10.1158/1078-0432.CCR-16-0134
Published: 02 January 2017
View article titled, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer
Open the PDF for A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer in another window
Journal Articles

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models

Teresa Troiani, Stefania Napolitano, Giulia Martini, Erika Martinelli, Claudia Cardone, Nicola Normanno, Donata Vitagliano, Floriana Morgillo, Francesca Fenizia, Matilde Lambiase, Luigi Formisano, Roberto Bianco, Davide Ciardiello, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4153–4164.
https://doi.org/10.1158/1078-0432.CCR-15-0211
Published: 14 September 2015
View article titled, Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models
Open the PDF for Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models in another window
Journal Articles

Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

Roberta Rosa, Roberta Marciano, Umberto Malapelle, Luigi Formisano, Lucia Nappi, Claudia D'Amato, Valentina D'Amato, Vincenzo Damiano, Gabriella Marfè, Silvana Del Vecchio, Antonella Zannetti, Adelaide Greco, Alfonso De Stefano, Chiara Carlomagno, Bianca Maria Veneziani, Giancarlo Troncone, Sabino De Placido, Roberto Bianco
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 138–147.
https://doi.org/10.1158/1078-0432.CCR-12-1050
Published: 02 January 2013
View article titled, Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models
Open the PDF for Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models in another window
Includes: Supplementary data